MARKET

IMDX

IMDX

Insight Molecular Diagnostics Inc.
NASDAQ
5.40
-0.19
-3.40%
After Hours: 5.40 0 0.00% 16:10 06/26 EDT
OPEN
5.41
PREV CLOSE
5.59
HIGH
5.72
LOW
5.27
VOLUME
82.26K
TURNOVER
--
52 WEEK HIGH
8.51
52 WEEK LOW
2.330
MARKET CAP
174.37M
P/E (TTM)
-3.6418
1D
5D
1M
3M
1Y
5Y
1D
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
Barchart · 6d ago
Weekly Report: what happened at IMDX last week (0615-0619)?
Weekly Report · 6d ago
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
TipRanks · 06/17 21:31
Insight Molecular Diagnostics shareholders approve 1,750,000-share increase to equity plan
PUBT · 06/17 20:06
Insight Molecular Diagnostics says Clinical Chemistry study shows 99.2% agreement between GraftAssure and rival NGS dd-cfDNA test at 0.5% threshold
PUBT · 06/16 20:05
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry
Barchart · 06/16 15:05
Weekly Report: what happened at IMDX last week (0608-0612)?
Weekly Report · 06/15 10:40
Insight Molecular Diagnostics says study shows GraftAssure CM-Score lifts kidney transplant rejection PPV to 81%
PUBT · 06/11 20:17
More
About IMDX
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Webull offers Insight Molecular Diagnostics Inc stock information, including NASDAQ: IMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMDX stock methods without spending real money on the virtual paper trading platform.